S
Samar Hamdy
Researcher at University of Alberta
Publications - 21
Citations - 1543
Samar Hamdy is an academic researcher from University of Alberta. The author has contributed to research in topics: PLGA & Antigen. The author has an hindex of 15, co-authored 21 publications receiving 1421 citations.
Papers
More filters
Journal ArticleDOI
Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations
TL;DR: PLGA-NPs containing antigens along with immunostimulatory molecules (adjuvants) can not only target antigen actively to DCs, but also provide immune activation and rescue impaired DCs from tumor-induced immuosupression.
Journal ArticleDOI
Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
Samar Hamdy,Ommoleila Molavi,Zengshuan Ma,Azita Haddadi,Aws Alshamsan,Zahra Gobti,Sara Elhasi,John Samuel,Afsaneh Lavasanifar +8 more
TL;DR: TRP2/7-acyl lipid A-NP treated group has shown immunostimulatory milieu at the tumor microenvironment, as evidenced by increased level of pro-inflammatory cytokines compared to control group.
Journal ArticleDOI
"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
TL;DR: Targeting antigens along with toll-like receptor ligands in PLGA nanoparticles to DCs is a promising approach for generating potent TH1 polarizing immune responses that can potentially override self-tolerance mechanisms and become beneficial in the immunotherapy of cancer and infectious diseases.
Journal ArticleDOI
Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.
TL;DR: Codelivery of antigen and MPLA in PLGA-NP offers an effective method for induction of potent antigen specific CD4(+) and CD8(+) T cell responses.
Journal ArticleDOI
The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
TL;DR: The lipid-modified PEI is a promising carrier for siRNA delivery and downregulation of STAT3 by polymer-mediated si RNA delivery is an effective strategy for cancer treatment especially when an optimum delivery system can potentiate the silencing activity of siRNA.